Form 4: Madrigal Pharmaceuticals Executive Carole Huntsman Reports Stock and Option Grants

Carole Huntsman, Chief Commercial Officer of Madrigal Pharmaceuticals, reports the acquisition of restricted stock units and stock options.

Summary

• On March 5, 2025, Carole Huntsman, Chief Commercial Officer of Madrigal Pharmaceuticals, reported transactions involving the company's securities.
• Huntsman was granted 3,386 restricted stock units (RSUs) at a price of $0.
• These RSUs vest in four equal installments of 25% on March 5 of 2026, 2027, 2028, and 2029, contingent upon continued service with the company.
• Huntsman also received an option to buy 5,703 shares of common stock at an exercise price of $347.28.
• The options vest 25% on March 5, 2026, and then 6.25% every three months thereafter, also contingent upon continued service.
• Following these transactions, Huntsman directly owns 11,990 shares of common stock and holds options for 5,703 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The document reflects standard executive compensation practices, which are generally viewed favorably as they align management interests with shareholder value. There are no indications of negative events or concerns.

Positives

• The grant of RSUs and stock options aligns the executive's interests with those of the shareholders, incentivizing long-term performance.
• The vesting schedules encourage continued service and commitment from the Chief Commercial Officer.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the granted securities.

Industry Context

Stock and option grants are a common practice in the pharmaceutical industry to attract and retain key executives, aligning their interests with the long-term success of the company, particularly during critical phases of drug development and commercialization.

Comparison to Industry Standards

• Executive compensation packages in the pharmaceutical industry often include a mix of salary, bonus, stock options, and restricted stock units.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize similar equity-based compensation to incentivize their executives.
• The vesting schedules and grant sizes are typically benchmarked against peer companies to ensure competitiveness and alignment with performance goals.

Stakeholder Impact

• Shareholders may view the equity grants positively as they incentivize management to drive long-term value.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates